In vivo experimental mouse model to test CD19CAR T cells generated with different methods

Anne Fåne; Marit Renée Myhre; Else Marit Inderberg; Sebastien Wälchli

doi:10.1016/bs.mcb.2021.11.001

In vivo experimental mouse model to test CD19CAR T cells generated with different methods

Methods Cell Biol. 2022:167:149-161. doi: 10.1016/bs.mcb.2021.11.001. Epub 2021 Dec 17.

Authors

Anne Fåne¹, Marit Renée Myhre¹, Else Marit Inderberg¹, Sebastien Wälchli²

Affiliations

¹ Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
² Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway. Electronic address: sebastien.walchli@rr-research.no.

PMID: 35152992
DOI: 10.1016/bs.mcb.2021.11.001

Abstract

Pre-clinical evaluation of CAR T cells includes procedures testing T-cell efficacy and safety in as close to real world conditions as possible. An important step in efficacy testing is the in vivo study, most often using immunodeficient murine models into which both the poison and the cure are injected; namely a human cancer cell line and genetically modified human T cells. The capacity of the T cells to control the cancer progression will provide information about the CAR T-cell efficacy. We here provide a protocol to test CAR T cells in vivo using the validated anti-B-cell marker CD19CAR and an aggressive lymphoma model.

Keywords: CAR; Chimeric antigen receptor; Immunotherapy; In vivo study; T cell; Xenograft model.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cell Line
Cell Line, Tumor
Immunotherapy, Adoptive / methods
Mice
Neoplasms* / metabolism
Receptors, Antigen, T-Cell / metabolism
T-Lymphocytes* / metabolism

Substances

Receptors, Antigen, T-Cell